1,067 results on '"Damoiseaux, Robert"'
Search Results
102. Supplementary Fig. 3 from MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell–intrinsic Amplification of Type I IFN Signaling
103. Supplementary Data 1 from MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell–intrinsic Amplification of Type I IFN Signaling
104. Comparative Analysis of Molecular Pathogenic Mechanisms and Antiviral Development Targeting Old and New World Hantaviruses
105. FLECS Technology for High-Throughput Screening of Hypercontractile Cellular Phenotypes in Fibrosis: A Function-First Approach to Anti-Fibrotic Drug Discovery
106. NSC95397 is a Novel HIV Latency Reversing Agent
107. Abstract 1611: Statins inhibit the collaborative metastasis mediated by VHL heterogeneity in clear cell renal cell carcinoma (ccRCC) via a non-cholesterol pathway
108. Abstract 674: CRISPR and drug screens identify ERK as the mediator of IFNg-induced melanoma growth inhibition
109. Supplementary Figures 1 and 2 from Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
110. Data from Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
111. Figure S1 from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
112. Supplementary Figure Legends from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
113. Data from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
114. Supplementary Table 1 from Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
115. Data from Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
116. Supplementary Figure 2 from Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
117. Supplementary Figure 2 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
118. Data from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
119. Supplementary Figure 3 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
120. Supplementary Table 3 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
121. Figure S6 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
122. Supplementary Figure 1 from Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
123. Supplementary Table 1 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
124. Supplementary Methods, References and Legends from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
125. Supplementary Figure 1 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
126. Supplementary Figure 5 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
127. Supplementary Table 2 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
128. Supplementary Figure 7 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
129. Supplementary Figure 6 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
130. Supplementary Figure 4 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
131. Supplementary Table S1-S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
132. Supplementary Figure Legend from Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
133. Supplementary Methods and Figure Legend from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
134. Data from A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier
135. Supplementary Figure 2 from A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier
136. Supplementary Figure 1 from A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier
137. Supplementary Figure S1 from PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
138. Supplementary Figure 7 from A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier
139. Supplementary Figure 4 from A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier
140. Supplementary Methods from A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier
141. Supplementary Figure 3 from A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier
142. Supplementary Data from High-Throughput Screening Identifies Two Classes of Antibiotics as Radioprotectors: Tetracyclines and Fluoroquinolones
143. Supplementary Methods from PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
144. Supplementary Table S1 from PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
145. Supplementary Figure 5 from A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier
146. Supplementary Figure 6 from A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier
147. Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells
148. Low complexity domains of the nucleocapsid protein of SARS-CoV-2 form amyloid fibrils.
149. Osteopontin as a Biomarker in Chronic Kidney Disease.
150. Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.